Tuberculous meningitis: diagnosis and treatment overview

Grace E Marx, Edward D Chan, Grace E Marx, Edward D Chan

Abstract

Tuberculous meningitis (TBM) is the most common form of central nervous system tuberculosis (TB) and has very high morbidity and mortality. TBM is typically a subacute disease with symptoms that may persist for weeks before diagnosis. Characteristic cerebrospinal fluid (CSF) findings of TBM include a lymphocytic-predominant pleiocytosis, elevated protein, and low glucose. CSF acid-fast smear and culture have relatively low sensitivity but yield is increased with multiple, large volume samples. Nucleic acid amplification of the CSF by PCR is highly specific but suboptimal sensitivity precludes ruling out TBM with a negative test. Treatment for TBM should be initiated as soon as clinical suspicion is supported by initial CSF studies. Empiric treatment should include at least four first-line drugs, preferably isoniazid, rifampin, pyrazinamide, and streptomycin or ethambutol; the role of fluoroquinolones remains to be determined. Adjunctive treatment with corticosteroids has been shown to improve mortality with TBM. In HIV-positive individuals with TBM, important treatment considerations include drug interactions, development of immune reconstitution inflammatory syndrome, unclear benefit of adjunctive corticosteroids, and higher rates of drug-resistant TB. Testing the efficacy of second-line and new anti-TB drugs in animal models of experimental TBM is needed to help determine the optimal regimen for drug-resistant TB.

References

    1. Girgis NI, Sultan Y, Farid Z, et al. Tuberculous meningitis, Abbassia Fever Hospital—U.S. Naval Medical Research Unit No. 3—Cairo, Egypt, from 1976 to 1996. American Journal of Tropical Medicine and Hygiene. 1998;58(1):28–34.
    1. Rock RB, Hu S, Gekker G, et al. Mycobacterium tuberculosis-induced cytokine and chemokine expression by human microglia and astrocytes: effects of dexamethasone. Journal of Infectious Diseases. 2005;192(12):2054–2058.
    1. Verdon R, Chevret S, Laissy JP, Wolff M. Tuberculous meningitis in adults: review of 48 cases. Clinical Infectious Diseases. 1996;22(6):982–988.
    1. Kent SJ, Crowe SM, Yung A, Lucas CR, Mijch AM. Tuberculous meningitis: a 30-year review. Clinical Infectious Diseases. 1993;17(6):987–994.
    1. Bidstrup C, Andersen PH, Skinhøj P, Andersen ÅB. Tuberculous meningitis in a country with a low incidence of tuberculosis: still a serious disease and a diagnostic challenge. Scandinavian Journal of Infectious Diseases. 2002;34(11):811–814.
    1. Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP. Isoniazid-resistant tuberculous meningitis, United States, 1993–2005. Emerging Infectious Diseases. 2011;17(3):539–542.
    1. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998–2007. The New England Journal of Medicine. 2011;364(21):2016–2025.
    1. Rich AR, McCordock HA. The pathogenesis of tuberculous meningitis. Bulletin of the Johns Hopkins Hospital. 1933;52:5–37.
    1. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. The New England Journal of Medicine. 1992;326(10):668–672.
    1. Farer LS, Lowell AM, Meador MP. Extrapulmonary tuberculosis in the United States. American Journal of Epidemiology. 1979;109(2):205–217.
    1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. The New England Journal of Medicine. 2001;345(15):1098–1104.
    1. Farinha NJ, Razali KA, Holzel H, Morgan G, Novelli VM. Tuberculosis of the central nervous system in children: a 20-year survey. Journal of Infection. 2000;41(1):61–68.
    1. Alzeer AH, FitzGerald JM. Corticosteroids and tuberculosis: risks and use as adjunct therapy. Tubercle and Lung Disease. 1993;74(1):6–11.
    1. Henry M, Hlzman RS. Tuberculosis of the brain, meninges, and spinal cord. In: Rom WN, Garay SM, et al., editors. Tuberculosis. 2nd edition. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2004. pp. 445–464.
    1. Kumar R, Singh SN, Kohli N. A diagnostic rule for tuberculous meningitis. Archives of Disease in Childhood. 1999;81(3):221–224.
    1. Thwaites GE, Chau TTH, Stepniewska K, et al. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. The Lancet. 2002;360(9342):1287–1292.
    1. Iseman MD. A Clinician’s Guide to Tuberculosis. Baltimore, Md, USA: Lippincott Williams & Wilkins; 1999.
    1. Kennedy DH, Fallon RJ. Tuberculous meningitis. Journal of the American Medical Association. 1979;241(3):264–268.
    1. Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP. Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. British Medical Journal. 2010;341:p. c4451.
    1. Chan ED, Heifets L, Iseman MD. Immunologic diagnosis of tuberculosis: a review. Tubercle and Lung Disease. 2000;80(3):131–140.
    1. Gupta BK, Bharat A, Debapriya B, Baruah H. Adenosine deaminase levels in CSF of tuberculous meningitis patients. Journal of Clinical Medicine Research. 2010;2(5):220–224.
    1. Corral I, Quereda C, Navas E, et al. Adenosine deaminase activity in cerebrospinal fluid of HIV-infected patients: limited value for diagnosis of tuberculous meningitis. European Journal of Clinical Microbiology and Infectious Diseases. 2004;23(6):471–476.
    1. Thwaites GE, Caws M, Chau TTH, et al. Comparison of conventional bacteriology with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculosis chemotherapy. Journal of Clinical Microbiology. 2004;42(3):996–1002.
    1. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2003;3(10):633–643.
    1. Jonas V, Alden MJ, Curry JI, et al. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by amplification of rRNA. Journal of Clinical Microbiology. 1993;31(9):2410–2416.
    1. Kusum S, Aman S, Pallab R, et al. Multiplex PCR for rapid diagnosis of tuberculous meningitis. Journal of Neurology. 2011;258(10):1781–1787.
    1. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technology Assessment. 2007;11(3):1–196.
    1. Donald PR, Victor TC, Jordaan AM, Schoeman JF, van Helden PD. Polymerase chain reaction in the diagnosis of tuberculous meningitis. Scandinavian Journal of Infectious Diseases. 1993;25(5):613–617.
    1. Pienaar M, Andronikou S, van Toorn R. MRI to demonstrate diagnostic features and complications of TBM not seen with CT. Child’s Nervous System. 2009;25(8):941–947.
    1. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. Journal of Infection. 2009;59(3):167–187.
    1. Humphries M. The management of tuberculous meningitis. Thorax. 1992;47(8):577–581.
    1. American Thoracic Society. Treatment of tuberculosis. Morbidity and Mortality Weekly Report. 2003;52(RR-11):1–77.
    1. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-Exposed and HIV-Infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Morbidity and Mortality Weekly Report. Recommendations and Reports. 2009;58(RR-11):1–166.
    1. World Health Organization. Treatment of Tuberculosis: Guidelines. 4th edition 2010.
    1. DeVincenzo JP, Berning SE, Peloquin CA, Husson RN. Multidrug-resistant tuberculous meningitis: clinical problems and concentrations of second-line antituberculous medications. Annals of Pharmacotherapy. 1999;33(11):1184–1188.
    1. Alffenaar JWC, van Altena R, Bökkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clinical Infectious Diseases. 2009;49(7):1080–1082.
    1. Kelly JJ, Horowitz EA, Destache CJ, Fruin AH, Long VA. Diagnosis and treatment of complicated tubercular meningitis. Pharmacotherapy. 1999;19(10):1167–1172.
    1. Thwaites GE, Bhavnani SM, Chau TTH, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrobial Agents and Chemotherapy. 2011;55(7):3244–3253.
    1. Zuger A. Tuberculosis. In: Scheld WM, Whitley RJ, Marra CM, editors. Infections of the Central Nervous System. 3rd edition. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2004. pp. 441–460.
    1. Thwaites GE, Lan NTN, Dung NH, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. Journal of Infectious Diseases. 2005;192(1):79–88.
    1. Chan ED, Chatterjee D, Iseman MD, Heifets LB. Pyrazinamide, ethambutol, ethionamide, and aminoglycosides. In: Rom WN, Garay SM, editors. Tuberculosis. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2004. pp. 773–789.
    1. Heemskerk D, Day J, Chau TTH, et al. Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. Trials. 2011;12:p. 25.
    1. Gaillard JL, Silly C, le Masne A, et al. Cerebrospinal fluid penetration of Amikacin in children with community-acquired bacterial meningitis. Antimicrobial Agents and Chemotherapy. 1995;39(1):253–255.
    1. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis. 2010;90(5):279–292.
    1. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. The New England Journal of Medicine. 2009;360(23):2397–2405.
    1. Kaojarern S, Supmonchai K, Phuapradit P, Mokkhavesa C, Krittiyanunt S. Effect of steroids on cerebrospinal fluid penetration of antituberculous drugs in tuberculous meningitis. Clinical Pharmacology and Therapeutics. 1991;49(1):6–12.
    1. Hong L, Jiang W, Pan H, Jiang Y, Zeng S, Zheng W. Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese. Drug Metabolism and Disposition. 2011;39(10):1904–1909.
    1. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clinical Microbiology Reviews. 2010;23(4):858–883.
    1. Strausbaugh LJ, Mandaleris CD, Sande MA. Comparison of four aminoglycoside antibiotics in the therapy of experimental E. coli meningitis. Journal of Laboratory and Clinical Medicine. 1977;89(4):692–701.
    1. Ginsberg AM. Drugs in development for tuberculosis. Drugs. 2010;70(17):2201–2214.
    1. Rivers EC, Mancera RL. New anti-tuberculosis drugs with novel mechanisms of action. Current Medicinal Chemistry. 2008;15(19):1956–1967.
    1. Leung CC, Lam TH, Chan WM, et al. Diabetic control and risk of tuberculosis: a cohort study. American Journal of Epidemiology. 2008;167(12):1486–1494.
    1. de Gans J, van Beek D. Dexamethasone in adults with bacterial meningitis. The New England Journal of Medicine. 2002;347(20):1549–1556.
    1. Nguyen TH, Tran TH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. The New England Journal of Medicine. 2007;357(24):2431–2440.
    1. Brouwer MC, McIntyre P, de Gans J, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews. 2010;9 Article ID CD004405.
    1. Spapen H, van Berlaer G, Moens M, Hubloue I. Adjunctive steroid treatment in acute bacterial meningitis. “To do or not to do: that is the question”. Acta Clinica Belgica. 2011;66(1):42–45.
    1. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database of Systematic Reviews. 2008;(1):p. CD002244.
    1. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England Journal of Medicine. 2004;351(17):1741–1751.
    1. Girgis NI, Farid Z, Kilpatrick ME, Sultan Y, Mikhail IA. Dexamethasone adjunctive treatment for tuberculous meningitis. Pediatric Infectious Disease Journal. 1991;10(3):179–183.
    1. Curto M, Reali C, Palmieri G, et al. Inhibition of cytokines expression in human microglia infected by virulent and non-virulent mycobacteria. Neurochemistry International. 2004;44(6):381–392.
    1. Mastroianni CM, Paoletti F, Lichtner M, D’Agostino C, Vullo V, Delia S. Cerebrospinal fluid cytokines in patients with tuberculous meningitis. Clinical Immunology and Immunopathology. 1997;84(2):171–176.
    1. Tsenova L, Sokol K, Freedman VH, Kaplan G. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. Journal of Infectious Diseases. 1998;177(6):1563–1572.
    1. Tsenova L, Bergtold A, Freedman VH, Young RA, Kaplan G. Tumor necrosis factor α is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(10):5657–5662.
    1. Møller K, Larsen FS, Bie P, Skinhøj P. The syndrome of inappropriate secretion of antidiuretic hormone and fluid restriction in meningitis—how strong is the evidence? Scandinavian Journal of Infectious Diseases. 2001;33(1):13–26.
    1. Gelabert M, Castro-Gago M. Hydrocephalus and tuberculous meningitis in children. Report on 26 cases. Child’s Nervous System. 1988;4(5):268–270.
    1. Clark WC, Metcalf JC, Jr., Muhlbauer MS, Dohan FC, Jr., Robertson JH. Mycobacterium tuberculosis meningitis: a report of twelve cases and a literature review. Neurosurgery. 1986;18(5):604–610.
    1. Chugh AP, Husain M, Gupta RK, Ojha BK, Chandra A, Rastogi M. Surgical outcome of tuberculous meningitis hydrocephalus treated by endoscopic third ventriculostomy: prognostic factors and postoperative neuroimaging for functional assessment of ventriculostomy. Journal of Neurosurgery: Pediatrics. 2009;3(5):371–377.
    1. Kemaloglu S, Özkan U, Bukte Y, Ceviz A, Özates M. Timing of shunt surgery in childhood tuberculous meningitis with hydrocephalus. Pediatric Neurosurgery. 2002;37(4):194–198.
    1. Lamprecht D, Schoeman J, Donald P, Hartzenberg H. Ventriculoperitoneal shunting in childhood tuberculous meningitis. British Journal of Neurosurgery. 2001;15(2):119–125.
    1. Srikantha U, Morab JV, Sastry S, et al. Outcome of ventriculoperitoneal shunt placement in Grade IV tubercular meningitis with hydrocephalus: a retrospective analysis in 95 patients. Journal of Neurosurgery: Pediatrics. 2009;4(2):176–183.
    1. Garg RK, Sinha MK. Tuberculous meningitis in patients infected with human immunodeficiency virus. Journal of Neurology. 2011;258(1):3–13.
    1. Asselman V, Thienemann F, Pepper DJ, et al. Central nervous system disorders after starting antiretroviral therapy in South Africa. AIDS. 2010;24(18):2871–2876.
    1. Valin N, Pacanowski J, Denoeud L, et al. Risk factors for ’unmasking immune reconstitution inflammatory syndrome’ presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients. AIDS. 2010;24(10):1519–1525.
    1. Török ME, Yen NTB, Chau TTH, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clinical Infectious Diseases. 2011;52(11):1374–1383.
    1. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. The New England Journal of Medicine. 2010;362(8):697–706.
    1. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Morbidity and Mortality Weekly Report. Recommendations and Reports. 2009;58(RR-4):1–207.
    1. Caws M, Thwaites G, Stepniewska K, et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. Journal of Clinical Microbiology. 2006;44(11):3934–3939.
    1. Cecchini D, Ambrosioni J, Brezzo C, et al. Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. AIDS. 2007;21(3):373–374.
    1. Patel VB, Padayatchi N, Bhigjee AI, et al. Multidrug-resistant tuberculous meningitis in KwaZulu-Natal, South Africa. Clinical Infectious Diseases. 2004;38(6):851–856.
    1. Torok ME, Chau TTH, Mai PP, et al. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS ONE. 2008;3(3) Article ID e1772.
    1. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clinical Infectious Diseases. 2010;50(9):1288–1299.
    1. de Groote MA, Gilliland JC, Wells CL, et al. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis . Antimicrobial Agents and Chemotherapy. 2011;55(3):1237–1247.
    1. Tsenova L, Harbacheuski R, Moreira AL, et al. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infection and Immunity. 2006;74(4):2392–2401.
    1. Tsenova L, Harbacheuski R, Sung N, Ellison E, Fallows D, Kaplan G. BCG vaccination confers poor protection against M. tuberculosis HN878-induced central nervous system disease. Vaccine. 2007;25(28):5126–5132.
    1. van Well GTJ, Wieland CW, Florquin S, Roord JJ, van der Poll T, van Furth AM. A new murine model to study the pathogenesis of tuberculous meningitis. Journal of Infectious Diseases. 2007;195(5):694–697.
    1. Orme IM. The search for new vaccines against tuberculosis. Journal of Leukocyte Biology. 2001;70(1):1–10.
    1. Fine PEM. BCG: the challenge continues. Scandinavian Journal of Infectious Diseases. 2001;33(4):243–245.
    1. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. International Journal of Epidemiology. 1993;22(6):1154–1158.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner